Novo Nordisk partners with Variant Bio, paying up to $50M upfront for metabolic disease targets. Some funds will support Indigenous communities that provided data.
Metsera's MET-097i shows 11.3% weight loss in Phase 2a trial, beating Wegovy and Zepbound at 3 months, with potential for monthly dosing and no titration requirement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback